Biogen inks $380M Alzheimer's deal with Neurimmune

Biogen Idec has struck a deal with Switzerland's Neurimmune Therapeutics to develop antibodies that attack the amyloid beta plaque fingered as a prime culprit in the neurodegenerative symptoms of Alzheimer's. Neurimmune will employ its technology platform to identify antibodies that bind to the plaque in exchange for up to $380 million in total fees and milestones. There are no therapies approved to slow or stop the disease.

- see Biogen's release
- here's the AFX report for more info

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.